Rhenman & Partners Asset Management’s Krystal Biotech KRYS Stock Holding History

Rhenman & Partners Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.07M	Sell	16,325 -350	-2%	-$105K	0.57%	65
2026 Q1	$4.31M	Sell	16,675 -8,325	-33%	-$2.22M	0.53%	61
2025 Q4	$6.16M	Buy	25,000 +13,250	+113%	+$2.79M	0.58%	60
2025 Q3	$2.07M	Sell	11,750 -1,000	-8%	-$150K	0.23%	83
2025 Q2	$1.75M	Sell	12,750 -5,000	-28%	-$734K	0.22%	74
2025 Q1	$3.2M	Sell	17,750 -6,000	-25%	-$1.01M	0.37%	58
2024 Q4	$3.72M	Buy	23,750 +6,750	+40%	+$1.2M	0.38%	62
2024 Q3	$3.09M	Sell	17,000 -2,000	-11%	-$386K	0.25%	81
2024 Q2	$3.49M	Hold	19,000	–	–	0.34%	67
2024 Q1	$3.38M	Buy	+19,000	New	+$2.64M	0.32%	63

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Rhenman & Partners Asset Management's KRYS Position: Q2 2026 in Review

Rhenman & Partners Asset Management reduced its Krystal Biotech (KRYS) stake by 2.1% in Q2 2026, selling an estimated $105K and leaving 16,325 shares worth $6.07M. The position accounts for 0.57% of the portfolio, ranked #65.

Rhenman & Partners Asset Management first reported a position in KRYS in Q1 2024 and has held it in 10 quarters since. The position peaked at $6.16M in Q4 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Rhenman & Partners Asset Management held 16,325 shares of Krystal Biotech worth $6.07M as of Q2 2026.
Rhenman & Partners Asset Management sold 350 Krystal Biotech shares in Q2 2026, an estimated $105K.
Krystal Biotech made up 0.57% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #65 holding.
Rhenman & Partners Asset Management first reported a position in Krystal Biotech in Q1 2024 and has held it in 10 quarters since.
Rhenman & Partners Asset Management's Krystal Biotech position peaked at $6.16M in Q4 2025.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.